



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Polish innovative drug for the treatment of type II diabetes based on a mechanism of interaction through PPAR receptors - preclinical	Sectoral Operational Programme Increase of Economic Competitiveness 2004-2006, Priority 1. Development of entrepreneurship and innovation by strengthening business environment institutions. Measure 1.4. Strengthening co-operation between R & D sphere and the economy	Adamed Sp. z o.o.	17 052 067,78	7 526 888,47	01.02.2006 30.11.2008



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Development of Polish innovative drug for the treatment of central nervous system diseases: schizophrenia, depression and anxiety - preclinical	Technological Initiative I	Adamed Sp. z o.o.	27 800 889,00	16 402 520,00	01.05.2008 30.04.2013



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
3CLA - biotechnology, guided anti-cancer drug	Operational Programme Innovative Economy 2007-2013. Priority 1. Research and development of new technologies Measure 1.4. Support for special projects	Adamed Sp. z o.o.	54 354 582,14	27 177 118,67	22.10.2008 31.12.2015
Developing and implementing a package of cardiac drugs of new generation	Operational Programme Innovative Economy 2007-2013 under Measure 1.4 Support for special projects Priority Axis 1. Research and development of new technologies and Measure 4.1. Support for implementation of results of R & D Priority Axis 4. Investments in innovative undertakings	Adamed Sp. z o.o.	6 013 000,00	1 503 250,00	01.12.2009 30.06.2014
New drugs for the treatment of complex diseases of the cardiovascular system	Operational Programme Innovative Economy 2007-2013. Priority 1. Research and development of new technologies, Measure 1.4. Support for special projects	Adamed Sp. z o.o.	7 770 731,19	3 694 380,00	07.05.2012 31.12.2015
The latest generation of an inhalable medicament for the treatment of respiratory diseases	Operational Programme Innovative Economy 2007-2013. Priority 1. Research and development of new technologies, Measure 1.4. Support for special projects	Adamed Pharma S.A.	14 704 150,77	7 279 880,00	01.06.2012 31.12.2015
Development and validation in a real drug form technology complex	Innovative Economy Operational Programme 2007-2013. Measure 1.5 "System project of the National Centre for Research and Development". Project pilot "DEMONSTRATOR + Supporting scientific research and development works in demonstration scale"	Adamed Sp. z o.o.	5 480 100,00	1 370 025,00	01.05.2013 30.11.2015
Development and implementation of novel antidiyslipidemics	Innovative Economy Operational Programme 2007-2013. Measure 1.5 Sectoral programme INNOMED	Adamed Sp. z o.o.	12 269 400,00	3 096 804,00	10.07.2013 30.09.2017
Next generation anticancer bioconjugates	Innovative Economy Operational Programme 2007-2013. Measure 1.5 Sectoral programme INNOMED	Adamed Sp. z o.o.	19 942 700 ,00	9 971 350,00	01.03.2014 28.02.2019



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Development of new technologies protein carriers for use in anti-cancer therapies	Programme „INNOTECH”. In-Tech programme path	Adamed Sp. z o.o.	6 280 188,00	3 705 311,00	01.04.2012 31.03.2015



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Preclinical and clinical development of a new TRAIL-derived biomolecule, triggering multiple cell death pathways for therapy of cancer - comprehensive research network for early phase oncology clinical trials in Poland.	STRATEGMED program "Prevention and treatment of diseases of civilization" -Competition II	Consortium: Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology; and Adamed Sp. z o.o.	21 550 490,00	18 487 740,00 Grant for Adamed Sp. z o.o. 5 637 875,00	01.09.2015 31.08.2018



Project title	The support program	Name of the Beneficiary	Project value	The value of the grant	Duration of the Project
Preclinical development of novel anticancer drug based on p53 reactivation – Acronym: ONCO-p53	Programme INNOMED „Competition 2/1.2/2015_INNOMED”	Adamed Sp. z o.o.	17 872 355,17	9 999 811,38	01.01.2016 31.12.2019
Expansion and equipment of the Research and Development Centre of Pabianickie Pharmaceutical Plant Polfa S.A.	Operational Programme Smart Growth 2014-2020. Measure 2.1 "Support for investment in infrastructure, R & D enterprises"	Pabianickie Zakłady Farmaceutyczne Polfa S.A.	29 531 962,50	8 268 949,50	17.11.2015 31.12.2017
Development of innovative urological drug with Furazidin, as a response to growing drug-resistance of microorganisms that cause urinary tract infections	Operational Programme Smart Growth 2014-2020. Measure 1.1 "Projects R & D Enterprises", Measure 1.1.1 "Industrial research and development work carried out by undertakings"	Pabianickie Zakłady Farmaceutyczne Polfa S.A.	18 788 507,84	7 861 187,23	01.06.2016 31.01.2022
The development of innovative dermatological compositions for use in the course of radiotherapy	Operational Programme Smart Growth 2014-2020. Measure 4.1 "Research and development", Measure 4.1.2 "Regional Agenda for Research"	Consortium: Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology; and Pabianickie Zakłady Farmaceutyczne Polfa S.A.	3 083 609,44	2 060 705,81 Grant for PZF Polfa S.A. 1 162 262,81	01.08.2016 31.01.2019